[1]诸伟花,孟宇.肾康注射液联合前列地尔注射液治疗慢性肾炎患者的疗效及对炎症因子水平的影响▲[J].内科,2019,14(06):648-650.[doi:DOI:10.16121/j.cnki.cn45-1347/r.2019.06.06]
 ZHU Weihua,MENG Yu.Efficacy of Shenkang injection combined with alprostadil injection on chronic nephritis and its effect on inflammatory factor levels[J].Internal Medicine of China,2019,14(06):648-650.[doi:DOI:10.16121/j.cnki.cn45-1347/r.2019.06.06]
点击复制

肾康注射液联合前列地尔注射液治疗慢性肾炎患者的疗效及对炎症因子水平的影响▲()
分享到:

《内科》[ISSN:1006-6977/CN:61-1281/TN]

卷:
14卷
期数:
2019年06
页码:
648-650
栏目:
论著
出版日期:
2019-12-30

文章信息/Info

Title:
Efficacy of Shenkang injection combined with alprostadil injection on chronic nephritis and its effect on inflammatory factor levels
文章编号:
1673-7768(2019)06-0648-03
作者:
诸伟花1孟宇2
1 河源市人民医院血液净化室,广东省河源市517000;2 广州华侨医院&暨南大学附属第一医院肾内科,广东省广州市510630
Author(s):
ZHU Weihua1 MENG Yu2
1 Blood Decontamination Room, Heyuan People′s Hospital, Heyuan 517000, Guangdong province, China; 2 Department of Renal Medicine, Guangzhou Overseas Chinese Hospital & the First Affiliated hospital of Jinan University, Guangzhou 510630, Guangdong province, China
关键词:
慢性肾炎肾康注射液前列地尔注射液炎症因子
Keywords:
Chronic nephritis Shenkang injection Alprostadil injection Inflammatory factors
分类号:
R 692.3
DOI:
DOI:10.16121/j.cnki.cn45-1347/r.2019.06.06
文献标志码:
A
摘要:
目的探讨肾康注射液联合前列地尔注射液治疗慢性肾炎的疗效以及对患者炎症因子水平的影响。方法选取2018年1~12月本院收治的慢性肾炎患者120例,采用随机数字表法分为观察组与对照组,每组60例。两组患者均给予消肿利尿、控制血压、控制血糖及低盐低蛋白饮食等基础治疗。在此基础上,对照组患者给予前列地尔注射液治疗,观察组患者给予前列地尔注射液+肾康注射液治疗,连续治疗14 d。比较两组患者的疗效及炎症因子水平的变化情况。结果观察组患者的治疗总有效率(95.0%)显著高于对照组(81.7%),差异有统计学意义(P<0.05)。治疗前,两组患者的血清白介素-18(IL-18)、肿瘤坏死因子-α(TNF-α)、超敏-C反应蛋白(hs-CRP)水平比较,差异无统计学意义(P>0.05);治疗14 d后,两组患者的血清IL-18、TNF-α、hs-CRP水平均显著降低,观察组患者的水平显著低于对照组,差异有统计学意义(P<0.05)。结论在给予基础治疗的前提下,肾康注射液联合前列地尔注射液治疗慢性肾炎患者临床疗效显著,可明显降低患者的炎症因子水平。
Abstract:
ObjectiveTo investigate the therapeutic effect of Shenkang injection combined with alprostadil injection on chronic nephritis and its effect on the level of inflammatory factors. MethodsA total of 120 patients with chronic nephritis admitted to our hospital from January to December 2018 were selected, and were divided into observation group and control group by random number table method, with 60 cases in each group. Patients in both groups were administered basic treatments including swelling and diuresis, blood pressure control, blood glucose control, as well as low-salt and low-protein diet, based on which patients in the control group were administered alprostadil injection, whereas patients in the observation group were administered alprostadil injection + Shenkang injection, for fourteen-day continuous treatment. The efficacy and the changes of inflammatory factor levels were compared between the two groups. ResultsThe total effective rate of treatment in the observation group was significantly higher than that in the control group (95.0% vs. 81.7%), with the statistically significant difference (P<0.05). Before treatment, there were no significant differences in serum interleukin-18 (IL-18), tumor necrosis factor-α (TNF-α), and high-sensitivity C-reactive protein (hs-CRP) levels between the two groups (P>0.05). After 14 days of treatment, the serum IL-18, TNF-α, and hs-CRP levels of the two groups decreased significantly, and the levels in the observation group were significantly lower than those in the control group, with the statistically significant differences (P<0.05). ConclusionOn the premise of basic treatment administration, employing Shenkang injection combined with alprostadil injection has a prominently clinical efficacy in patients with chronic nephritis, for it can obviously decrease the levels of inflammatory factors.

备注/Memo

备注/Memo:
基金项目:河源市社会发展科学技术项目(河科2016-56-27)
更新日期/Last Update: 2019-12-31